Loading market dashboard
Adaptive Biotechnologies Corporation
ADPTHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Adaptive Biotechnologies NASDAQ: ADPT Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair's Growth Stock Conference.
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm.
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago.
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. “We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development.
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring.
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.
57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026. This sale represented 12.29% of Rubinstein's direct holdings at the time, reducing her directly held Common Stock to 408,160 shares.
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the company's stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $13.15, for a total value of $250,639.00. Following the completion of the sale, the chief operating officer owned 421,174
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction on Friday, April 10th. The shares were sold at an average price of $12.77, for a total transaction of $243,396.20. Following the completion of the sale, the chief operating officer directly owned 425,512 shares in
The President and COO of Adaptive Biotechnologies Corporation reported the sale of 38,120 shares for about $554,000, based on a weighted average transaction price of $14.53 per share across April 1–2, 2026. This sale represented 7.85% of Rubinstein's direct Common Stock holdings, reducing her direct position to 447,202 shares post-transaction.
JPMorgan Chase and Co. lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 77.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 235,668 shares of the company's stock after selling 799,246 shares during the quarter. JPMorgan Chase and Co.
81,342 shares were sold for a total value of ~$1.21 million across multiple transactions from March 6 to March 10, 2026. The sale represented 11.22% of Rubinstein's direct holdings, reducing her direct ownership to 643,471 shares post-transaction.
An executive at Adaptive Biotechnologies reported the sale of 179,703 shares for about $2.37 million, based on a weighted average price of around $13.21 per share during March 11–13, 2026. This sale was executed directly and arose from the exercise and immediate sale of option-derived Common Stock; no indirect (e.g.
Francis Lo, Chief People Officer at Adaptive Biotechnologies (ADPT +0.00%), reported the sale of a combined 68,667 shares of common stock across two transactions in early March 2026, as disclosed in a pair of SEC Form 4 filings.
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cinctive Capital Management LP trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 49.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 310,313 shares of the company's stock after selling 305,431 shares during the period. Cinctive Capital Management LP owned 0.20% of Adaptive
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 141,583 shares of the firm's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the transaction, the chief operating officer owned 516,610 shares in the company, valued
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) insider Harlan Robins sold 470,266 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $6,193,403.22. Following the completion of the transaction, the insider owned 1,522,058 shares in the company,
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 470,167 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,192,099.39. Following the completion of the transaction, the chief executive officer directly owned 2,301,113 shares in
